AstraZeneca PLC (NASDAQ:AZN) Q4 2022 Earnings Conference Call February 9, 2023 6:45 AM ET
Company Participants
Andy Barnett - Head of Investor Relations
Pascal Soriot - Executive Director & Chief Executive Officer
Aradhana Sarin - Executive Director & Chief Financial Officer
David Fredrickson - Executive Vice President of Oncology Business Unit
Susan Galbraith - Executive Vice President of Oncology Research & Development
Ruud Dobber - Executive Vice President of BioPharmaceuticals Business Unit
Menelas Pangalos - Executive Vice President of BioPharmaceuticals R&D
Marc Dunoyer - Chief Executive Officer of Alexion
Iskra Reic - Executive Vice President of Vaccines & Immune Therapies
Leon Wang - Executive Vice President of International & China President
Conference Call Participants
Andrew Baum - Citi
Mattias Häggblom - Handelsbanken
Timothy Anderson - Wolfe Research
Luisa Hector - Berenberg
James Gordon - JPMorgan
Christopher Uhde - SEB
Eric Le Berrigaud - Stifel
Mark Purcell - Morgan Stanley
Michael Leuchten - UBS
Richard Parkes - BNP Paribas Exane
Seamus Fernandez - Guggenheim
Jo Walton - Credit Suisse
Emmanuel Papadakis - Deutsche Bank
Operator
Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central Europe and good evening to those listening in Asia. Welcome, ladies and gentlemen, to AstraZeneca's Full Year and Q4 2022 Results Conference Call for investors and analysts.
Before I hand the call over to AstraZeneca, I'd like to read the safe harbor statement. The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially
- Read more current AZN analysis and news
- View all earnings call transcripts